for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cancer Genetics Inc

CGIX.OQ

Latest Trade

0.15USD

Change

0.00(0.00%)

Volume

40,138

Today's Range

--

 - 

--

52 Week Range

0.09

 - 

0.91

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Cancer Genetics Posts Q2 Loss Per Share Of $0.01

Aug 20 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATE.Q2 LOSS PER SHARE $0.01.QUARTERLY REVENUE$1.5 MILLION VERSUS $1.3 MILLION.CASH AND CASH EQUIVALENTS AS OF JUNE 30, 2019 TOTALED $0.7 MILLION, COMPARED TO $0.2 MILLION AS OF DECEMBER 31, 2018..

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15 (Reuters) - Interpace Diagnostics Group Inc <IDXG.O>::INTERPACE DIAGNOSTICS ACQUIRES CANCER GENETICS’ BIOPHARMA SERVICES BUSINESS SUPPORTED BY INVESTMENT FROM AMPERSAND CAPITAL PARTNERS.INTERPACE DIAGNOSTICS GROUP INC - DEAL FOR $23.5 MILLION.INTERPACE DIAGNOSTICS - PRIVATE EQUITY FIRM IN DIAGNOSTIC/BIOPHARMA SECTOR, TO INVEST $27 MILLION IN TWO TRANCHES OF NEWLY ISSUED CONVERTIBLE PREFERRED STOCK.INTERPACE DIAGNOSTICS - UNDER TERMS, MADE ADDITIONAL PAYMENT OF ABOUT $4.5 MILLION TO CANCER GENETICS.

Cancer Genetics Reports Q1 Loss Per Share Of $0.90

May 20 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATE.Q1 LOSS PER SHARE $0.90.Q1 REVENUE FELL 10.8 PERCENT TO $6.8 MILLION.CONTINUE TO WORK WITH RAYMOND JAMES ON A STRATEGIC TRANSACTION.

Cancer Genetics Reports Q4 Loss Per Share $0.14

April 16 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES STRATEGIC BUSINESS UPDATES.Q4 LOSS PER SHARE $0.14.QTRLY REVENUE INCREASED SEQUENTIALLY BY 15%, FROM $5.9 MILLION IN Q3 TO $6.8 MILLION IN Q4.CONTINUES TO ENGAGE RAYMOND JAMES & ASSOCIATES, INC. AS A FINANCIAL ADVISOR TO ASSIST WITH EVALUATING OPTIONS.OPTIONS MAY INCLUDE RAISING ADDITIONAL CAPITAL, ACQUISITION OF ANOTHER COMPANY AND / OR COMPLEMENTARY ASSETS.OPTIONS MAY ALSO INCLUD SALE OF COMPANY, OR ANOTHER TYPE OF STRATEGIC PARTNERSHIP.

Cancer Genetics Announces Pricing Of $3.5 Million Public Offering Of Common Stock

Jan 28 (Reuters) - :CANCER GENETICS, INC. ANNOUNCES PRICING OF $3.5 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 15.2 MILLION COMMON SHARES PRICED AT $0.23 PER SHARE.

Cancer Genetics, Inc. Announces Proposed Public Offering Of Common Stock

Jan 28 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CANCER GENETICS INC - INTENDS TO USE NET PROCEEDS FROM OFFERING TO PAY ANY AMOUNTS REQUIRED TO PAY TO LENDERS, OTHERS.

Cancer Genetics & Certain Units Entered Forbearance & 5th Amendment To Amended & Restated Loan & Security Agreement

Jan 16 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS - CO, CERTAIN UNITS ENTERED FORBEARANCE & 5TH AMENDMENT TO AMENDED & RESTATED LOAN & SECURITY AGREEMENT.CANCER GENETICS INC - AMENDMENT EXTENDS REVOLVING LINE MATURITY DATE TO APRIL 15, 2019.CANCER GENETICS - CO, CERTAIN UNITS ALSO ENTERED INTO FORBEARANCE AGREEMENT & MODIFICATION NO. 4 TO LOAN & SECURITY AGREEMENT DATED MARCH 22, 2017.CANCER GENETICS - AMENDED LOAN AGREEMENT UNDER FORBEARANCE AGREEMENT & MODIFICATION NO. 4 IS INTEREST-ONLY $6 MILLION TERM LOAN, MATURES ON MARCH 22, 2020.

Sabby Management, Llc Reports 7.30 Percent Passive Stake In Cancer Genetics As Of Jan 10, 2019

Jan 10 (Reuters) - :SABBY MANAGEMENT, LLC REPORTS 7.30 PERCENT PASSIVE STAKE IN CANCER GENETICS INC AS OF JAN 10, 2019 - SEC FILING.

Cancer Genetics Announces Pricing Of Public Offering Of Common Stock

Jan 9 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS INC ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.ANNOUNCED PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 13.3 MILLION SHARES OF ITS COMMON STOCK AT A PRICE TO PUBLIC OF $0.225 PER SHARE.

Cancer Genetics, Inc. Announces Proposed Public Offering Of Common Stock

Jan 9 (Reuters) - Cancer Genetics Inc <CGIX.O>::CANCER GENETICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CANCER GENETICS INC - INTENDS TO USE NET PROCEEDS FROM THIS OFFERING TO PAY LENDER FEES AND OTHER COSTS INCURRED.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up